C
Clover Biopharmaceuticals Ltd
HKEX:2197
Clover Biopharmaceuticals Ltd
HKEX:2197
Price:
2.92
HKD
-5.81%
Market Closed
Market Cap:
HK$3.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Clover Biopharmaceuticals Ltd
HKEX:2197
|
CN |
|
A
|
Arsenal Digital Holdings Inc
OTC:ADHI
|
CA |
|
H
|
Hengdeli Holdings Ltd
HKEX:3389
|
HK |
|
Hayward Holdings Inc
NYSE:HAYW
|
US |
|
Y
|
Ynh Property Bhd
KLSE:YNHPROP
|
MY |
Balance Sheet
Balance Sheet Decomposition
Clover Biopharmaceuticals Ltd
Clover Biopharmaceuticals Ltd
Balance Sheet Decomposition is not available for
Clover Biopharmaceuticals Ltd
Clover Biopharmaceuticals Ltd
Balance Sheet
Clover Biopharmaceuticals Ltd
Clover Biopharmaceuticals Ltd
Currency: CNY
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
149
|
516
|
2 767
|
1 607
|
736
|
401
|
268
|
|
| Cash Equivalents |
149
|
516
|
2 767
|
1 607
|
736
|
401
|
268
|
|
| Short-Term Investments |
10
|
290
|
99
|
33
|
30
|
26
|
18
|
|
| Total Receivables |
0
|
0
|
100
|
43
|
62
|
53
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
24
|
41
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
38
|
12
|
0
|
|
| Inventory |
0
|
51
|
769
|
2 384
|
697
|
11
|
10
|
|
| Other Current Assets |
5
|
191
|
1 342
|
322
|
374
|
171
|
40
|
|
| Total Current Assets |
164
|
1 048
|
5 076
|
4 390
|
1 900
|
663
|
336
|
|
| PP&E Net |
17
|
87
|
222
|
242
|
162
|
116
|
94
|
|
| PP&E Gross |
17
|
87
|
222
|
242
|
162
|
116
|
0
|
|
| Accumulated Depreciation |
6
|
7
|
19
|
48
|
88
|
119
|
0
|
|
| Intangible Assets |
0
|
0
|
14
|
35
|
40
|
33
|
28
|
|
| Other Long-Term Assets |
4
|
52
|
33
|
28
|
0
|
0
|
0
|
|
| Total Assets |
186
N/A
|
1 188
+538%
|
5 346
+350%
|
4 695
-12%
|
2 101
-55%
|
813
-61%
|
458
-44%
|
|
| Liabilities | ||||||||
| Accounts Payable |
7
|
34
|
589
|
857
|
373
|
209
|
167
|
|
| Accrued Liabilities |
0
|
1
|
6
|
6
|
3
|
1
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
294
|
308
|
74
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
4
|
21
|
24
|
19
|
12
|
11
|
|
| Other Current Liabilities |
19
|
27
|
1 532
|
1 648
|
1 700
|
1 700
|
1 573
|
|
| Total Current Liabilities |
27
|
67
|
2 148
|
2 829
|
2 277
|
1 908
|
1 751
|
|
| Long-Term Debt |
209
|
1 145
|
46
|
37
|
8
|
3
|
0
|
|
| Other Liabilities |
17
|
958
|
1 932
|
2 497
|
549
|
538
|
505
|
|
| Total Liabilities |
254
N/A
|
2 170
+754%
|
4 127
+90%
|
5 363
+30%
|
2 834
-47%
|
2 449
-14%
|
2 255
-8%
|
|
| Equity | ||||||||
| Common Stock |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Retained Earnings |
68
|
981
|
6 860
|
9 359
|
9 501
|
10 421
|
1 798
|
|
| Additional Paid In Capital |
0
|
0
|
7 972
|
8 562
|
8 621
|
8 654
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
2
|
245
|
219
|
147
|
130
|
0
|
|
| Total Equity |
68
N/A
|
983
-1 349%
|
1 219
N/A
|
668
N/A
|
733
-10%
|
1 636
-123%
|
1 797
-10%
|
|
| Total Liabilities & Equity |
186
N/A
|
1 188
+538%
|
5 346
+350%
|
4 695
-12%
|
2 101
-55%
|
813
-61%
|
458
-44%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
1 158
|
1 158
|
1 158
|
1 293
|
1 296
|
1 297
|
1 298
|
|
Switch to:
Switch to:
See Also
Discover More
